Metabolism and Disposition Kinetics of Nicotine
暂无分享,去创建一个
[1] R. T. Fowler. A redetermination of the ionization constants of nicotine , 2007 .
[2] N. Benowitz,et al. Influence of menstrual cycle on cytochrome P450 2A6 activity and cardiovascular effects of nicotine , 2005, Clinical pharmacology and therapeutics.
[3] Jun-yan Hong,et al. METABOLISM OF NICOTINE AND COTININE BY HUMAN CYTOCHROME P450 2A13 , 2005, Drug Metabolism and Disposition.
[4] W. S. Caldwell,et al. Comparison of measured and FTC-predicted nicotine uptake in smokers , 1995, Psychopharmacology.
[5] K. Kudo,et al. Simultaneous determination of nicotine and cotinine in various human tissues using capillary gas chromatography/mass spectrometry , 1994, International Journal of Legal Medicine.
[6] M. Fukumoto. Nicotine and cotinine , 2005 .
[7] C. Feyerabend,et al. Nasal nicotine spray: a rapid nicotine delivery system , 2005, Psychopharmacology.
[8] H. McLeod,et al. A novel polymorphism of human CYP2A6 gene CYP2A6*17 has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo , 2004, Clinical pharmacology and therapeutics.
[9] R. Tyndale,et al. Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. , 2004, Pharmacogenetics.
[10] N. Benowitz,et al. Mentholated Cigarette Smoking Inhibits Nicotine Metabolism , 2004, Journal of Pharmacology and Experimental Therapeutics.
[11] N. Benowitz,et al. Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity , 2004, Clinical pharmacology and therapeutics.
[12] M. Ingelman-Sundberg,et al. Polymorphic NF-Y dependent regulation of human nicotine C-oxidase (CYP2A6). , 2004, Pharmacogenetics.
[13] Kyle Christian,et al. Interaction of heterogeneous nuclear ribonucleoprotein A1 with cytochrome P450 2A6 mRNA: implications for post-transcriptional regulation of the CYP2A6 gene. , 2004, Molecular pharmacology.
[14] D. Greenblatt,et al. Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes. , 2004, Pharmacogenetics.
[15] M. Nishijo,et al. Effects of chronic exposure to low-level cadmium on renal tubular function and CYP2A6-mediated coumarin metabolism in healthy human subjects. , 2004, Toxicology letters.
[16] M. Lang,et al. Acute cadmium chloride administration induces hepatic and renal CYP2A5 mRNA, protein and activity in the mouse: involvement of transcription factor NRF2. , 2004, Toxicology letters.
[17] M. Ingelman-Sundberg,et al. A nicotine C‐oxidase gene (CYP2A6) polymorphism important for promoter activity , 2004, Human mutation.
[18] Xiaodong Zhang,et al. Nicotine-related alkaloids and metabolites as inhibitors of human cytochrome P-450 2A6. , 2004, Biochemical pharmacology.
[19] N. Benowitz,et al. Oral contraceptives induce CYP2A6 activity and accelerate nicotine metabolism , 2004 .
[20] P. Peeters,et al. Pharmacokinetics and safety of mirtazapine in caucasian and japanese young healthy male volunteers , 2004 .
[21] K. Cummings,et al. Epidemiology of menthol cigarette use. , 2004, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.
[22] Jia-Long Fang,et al. Correlation between UDP-Glucuronosyltransferase Genotypes and 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanone Glucuronidation Phenotype in Human Liver Microsomes , 2004, Cancer Research.
[23] G. Neurath. Aspects of the oxidative metabolism of nicotine , 1994, The clinical investigator.
[24] S. Nasirov,et al. Anabasine hydrochloride — A new antismoking agent , 1978, Pharmaceutical Chemistry Journal.
[25] F. Kratz. Coumarin-7-hydroxylase activity in microsomes from needle biopsies of normal and diseased human liver , 1976, European Journal of Clinical Pharmacology.
[26] M. Bende,et al. Absolute bioavailability of nicotine applied to different nasal regions , 2004, European Journal of Clinical Pharmacology.
[27] O. Pelkonen,et al. Interindividual variability of coumarin 7-hydroxylation in a Turkish population , 2004, European Journal of Clinical Pharmacology.
[28] R. Obach,et al. Potent inhibition of human liver aldehyde oxidase by raloxifene. , 2004, Drug metabolism and disposition: the biological fate of chemicals.
[29] K. Jain. Modulators of nicotinic acetylcholine receptors as analgesics. , 2004, Current opinion in investigational drugs.
[30] H. Sigusch,et al. Grapefruit juice inhibits 7-hydroxylation of coumarin in healthy volunteers , 2004, European Journal of Clinical Pharmacology.
[31] R. Frecker,et al. Effect of cimetidine and ranitidine on the hepatic and renal elimination of nicotine in humans , 2004, European Journal of Clinical Pharmacology.
[32] J. Fourtillan,et al. Effect of ponsinomycin on cyclosporin pharmacokinetics , 2004, European Journal of Clinical Pharmacology.
[33] P. Daenens,et al. Kinetics of cotinine after oral and intravenous administration to man , 2004, European Journal of Clinical Pharmacology.
[34] Rosette Lidereau,et al. Relationship between intratumoral expression of genes coding for xenobiotic-metabolizing enzymes and benefit from adjuvant tamoxifen in estrogen receptor alpha-positive postmenopausal breast carcinoma , 2004, Breast Cancer Research.
[35] B. Ring,et al. Hepatic CYP2B6 Expression: Gender and Ethnic Differences and Relationship to CYP2B6 Genotype and CAR (Constitutive Androstane Receptor) Expression , 2003, Journal of Pharmacology and Experimental Therapeutics.
[36] R. Tyndale,et al. The effect of methoxsalen on nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) metabolism in vivo. , 2003, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.
[37] C. B. Pickett,et al. Regulatory mechanisms controlling gene expression mediated by the antioxidant response element. , 2003, Annual review of pharmacology and toxicology.
[38] J. Casida,et al. Selective toxicity of neonicotinoids attributable to specificity of insect and mammalian nicotinic receptors. , 2003, Annual review of entomology.
[39] W. Tan,et al. Substantial reduction in risk of lung adenocarcinoma associated with genetic polymorphism in CYP2A13, the most active cytochrome P450 for the metabolic activation of tobacco-specific carcinogen NNK. , 2003, Cancer research.
[40] S. Murphy,et al. N-glucuronidation of trans-3'-hydroxycotinine by human liver microsomes. , 2003, Chemical Research in Toxicology.
[41] S. Murphy,et al. N-glucuronidation of nicotine and cotinine by human liver microsomes and heterologously expressed UDP-glucuronosyltransferases. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[42] T. Nolin,et al. Hepatic drug metabolism and transport in patients with kidney disease. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[43] H. Yamazaki,et al. Decreased coumarin 7-hydroxylase activities and CYP2A6 expression levels in humans caused by genetic polymorphism in CYP2A6 promoter region (CYP2A6*9). , 2003, Pharmacogenetics.
[44] I. Cascorbi. Pharmacogenetics of cytochrome P4502D6: genetic background and clinical implication , 2003, European journal of clinical investigation.
[45] K. Strahs,et al. Pharmacokinetics of a nicotine polacrilex lozenge. , 2003, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.
[46] Qing-Yu Zhang,et al. Immunoblot analysis and immunohistochemical characterization of CYP2A expression in human olfactory mucosa. , 2003, Biochemical pharmacology.
[47] C. Pomerleau,et al. Nicotine metabolite ratio as a predictor of cigarette consumption. , 2003, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.
[48] Stephen S. Hecht,et al. Tobacco carcinogens, their biomarkers and tobacco-induced cancer , 2003, Nature Reviews Cancer.
[49] C. Guillemette,et al. Novel Functional Polymorphisms in the UGT1A7 and UGT1A9 Glucuronidating Enzymes in Caucasian and African-American Subjects and Their Impact on the Metabolism of 7-Ethyl-10-hydroxycamptothecin and Flavopiridol Anticancer Drugs , 2003, Journal of Pharmacology and Experimental Therapeutics.
[50] C. Derauf,et al. Agreement between maternal self-reported ethanol intake and tobacco use during pregnancy and meconium assays for fatty acid ethyl esters and cotinine. , 2003, American journal of epidemiology.
[51] F. Berthou,et al. Diversity of selective environmental substrates for human cytochrome P450 2A6: alkoxyethers, nicotine, coumarin, N-nitrosodiethylamine, and N-nitrosobenzylmethylamine. , 2003, Toxicology letters.
[52] E. Domino,et al. Comparative American and Japanese tobacco smoke uptake parameters after overnight tobacco deprivation , 2003, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[53] M. Caggana,et al. Single nucleotide polymorphisms of the human cyp2a13 gene: evidence for a null allele. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[54] A. Poso,et al. Predictive value of comparative molecular field analysis modelling of naphthalene inhibition of human CYP2A6 and mouse CYP2A5 enzymes. , 2003, Toxicology in vitro : an international journal published in association with BIBRA.
[55] J. Goldstein,et al. Identification of constitutive androstane receptor and glucocorticoid receptor binding sites in the CYP2C19 promoter. , 2003, Molecular pharmacology.
[56] J. Pankow,et al. Percent free base nicotine in the tobacco smoke particulate matter of selected commercial and reference cigarettes. , 2003, Chemical research in toxicology.
[57] Xiaodong Zhang,et al. Inhibition of human liver microsomal (S)-nicotine oxidation by (-)-menthol and analogues. , 2003, Chemical research in toxicology.
[58] S. Tokudome,et al. Effects of polymorphism in Promoter Region of Human CYP2A6 Gene (CYP2A6*9) on Expression Level of Messenger Ribonucleic Acid and Enzymatic Activity In Vivo and In Vitro , 2003, Clinical pharmacology and therapeutics.
[59] D. Mash,et al. Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain , 2003, Neuropharmacology.
[60] T. Thum,et al. Verapamil: metabolism in cultures of primary human coronary arterial endothelial cells. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[61] R. Tyndale,et al. Decreasing smoking behaviour and risk through CYP2A6 inhibition. , 2003, Drug discovery today.
[62] R. Obach,et al. Ziprasidone Metabolism, Aldehyde Oxidase, and Clinical Implications , 2003, Journal of clinical psychopharmacology.
[63] R. Tyndale,et al. CYP2E1*1D regulatory polymorphism: association with alcohol and nicotine dependence. , 2003, Pharmacogenetics.
[64] L. Moore,et al. Identification of a Novel Human Constitutive Androstane Receptor (CAR) Agonist and Its Use in the Identification of CAR Target Genes* , 2003, The Journal of Biological Chemistry.
[65] C. Jepson,et al. Individual differences in nicotine intake per cigarette. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[66] Hongbing Wang,et al. Glucocorticoid receptor enhancement of pregnane X receptor-mediated CYP2B6 regulation in primary human hepatocytes. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[67] Sharon Miksys,et al. Brain CYP2E1 is induced by nicotine and ethanol in rat and is higher in smokers and alcoholics , 2003, British journal of pharmacology.
[68] Liang-Shang Gan,et al. Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[69] Ricarda Thier,et al. The cytochrome P-450 isoenzyme CYP2E1 in the biological processing of industrial chemicals: consequences for occupational and environmental medicine , 2003, International archives of occupational and environmental health.
[70] A. Burnett,et al. Safety, Pharmacokinetics, and Effects on Cognitive Function of Multiple Doses of GTS-21 in Healthy, Male Volunteers* , 2003, Neuropsychopharmacology.
[71] J. Tredger,et al. Induction of cytochrome P450 enzymes in cultured precision-cut human liver slices. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[72] S. Anttila,et al. Regulation of CYP3A5 by Glucocorticoids and Cigarette Smoke in Human Lung-Derived Cells , 2003, Journal of Pharmacology and Experimental Therapeutics.
[73] L. Lash,et al. Human Kidney Flavin-Containing Monooxygenases and Their Potential Roles in Cysteine S-Conjugate Metabolism and Nephrotoxicity , 2003, Journal of Pharmacology and Experimental Therapeutics.
[74] A. Poso,et al. More potent inhibition of human CYP2A6 than mouse CYP2A5 enzyme activities by derivatives of phenylethylamine and benzaldehyde , 2003, Xenobiotica; the fate of foreign compounds in biological systems.
[75] R. Tyndale,et al. Down-regulation of hepatic nicotine metabolism and a CYP2A6-like enzyme in African green monkeys after long-term nicotine administration. , 2003, Molecular pharmacology.
[76] M. Nakajima,et al. Characterization of nicotine and cotinine N-glucuronidations in human liver microsomes. , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[77] E. Hawes,et al. Microsomal N-glucuronidation of nicotine and cotinine: human hepatic interindividual, human intertissue, and interspecies hepatic variation. , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[78] R. Tyndale,et al. CYP2A6 genetic variation and potential consequences. , 2002, Advanced drug delivery reviews.
[79] M. Nakajima,et al. Genetic polymorphisms in human CYP2A6 gene causing impaired nicotine metabolism. , 2002, British journal of clinical pharmacology.
[80] R. Tyndale,et al. Factors influencing cotinine half-life during smoking abstinence in African American and Caucasian women. , 2002, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.
[81] G. Scherer,et al. Simultaneous determination of nicotine and eight nicotine metabolites in urine of smokers using liquid chromatography-tandem mass spectrometry. , 2002, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[82] J. Cashman,et al. Interindividual differences of human flavin-containing monooxygenase 3: genetic polymorphisms and functional variation. , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[83] L. Dwoskin,et al. Total Cotinine in Plasma: A Stable Biomarker for Exposure to Tobacco Smoke , 2002, Journal of clinical psychopharmacology.
[84] M. Ingelman-Sundberg,et al. Characterization of a novel CYP2A7/CYP2A6 hybrid allele (CYP2A6*12) that causes reduced CYP2A6 activity , 2002, Human mutation.
[85] M. Quik,et al. Nicotine and nicotinic receptors; relevance to Parkinson's disease. , 2002, Neurotoxicology.
[86] E. Hawes,et al. N-glucuronidation of nicotine and cotinine in human: formation of cotinine glucuronide in liver microsomes and lack of catalysis by 10 examined UDP-glucuronosyltransferases. , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[87] Jun Yokota,et al. Genetic polymorphism of CYP2A6 gene and tobacco-induced lung cancer risk in male smokers. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[88] Sharon Miksys,et al. Regional and cellular expression of CYP2D6 in human brain: higher levels in alcoholics , 2002, Journal of neurochemistry.
[89] Hideyuki Saito,et al. Transport Mechanisms of Nicotine across the Human Intestinal Epithelial Cell Line Caco-2 , 2002, Journal of Pharmacology and Experimental Therapeutics.
[90] P. Steenkamp,et al. Accidental fatal poisoning by Nicotiana glauca: identification of anabasine by high performance liquid chromatography/photodiode array/mass spectrometry. , 2002, Forensic science international.
[91] E. Richter,et al. New sources of dietary myosmine uptake from cereals, fruits, vegetables, and milk. , 2002, Journal of agricultural and food chemistry.
[92] H. Saito,et al. cDNA cloning, functional characterization, and tissue distribution of an alternatively spliced variant of organic cation transporter hOCT2 predominantly expressed in the human kidney. , 2002, Journal of the American Society of Nephrology : JASN.
[93] R. Zhu,et al. Phenotypic polymorphism of CYP2A6 activity in a Chinese population , 2002, European Journal of Clinical Pharmacology.
[94] Hiroshi Yamazaki,et al. A novel mutant allele of the CYP2A6 gene (CYP2A6*11 ) found in a cancer patient who showed poor metabolic phenotype towards tegafur. , 2002, Pharmacogenetics.
[95] T. Sueyoshi,et al. Residue threonine 350 confers steroid hormone responsiveness to the mouse nuclear orphan receptor CAR. , 2002, Molecular pharmacology.
[96] M. Utt,et al. Separation and surveys of proteins of Helicobacter pylori. , 2002, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[97] R. Peng,et al. In vitro metabolic characteristics of cytochrome P-450 2A6 in Chinese liver microsomes. , 2002, Acta pharmacologica Sinica.
[98] N. Benowitz,et al. Accelerated metabolism of nicotine and cotinine in pregnant smokers. , 2002, The Journal of pharmacology and experimental therapeutics.
[99] M. Lang,et al. CYP2A6/2A7 and CYP2E1 expression in human oesophageal mucosa: regional and inter-individual variation in expression and relevance to nitrosamine metabolism. , 2002, Carcinogenesis.
[100] H. Yamazaki,et al. Variation in coumarin 7-hydroxylase activity associated with genetic polymorphism of cytochrome P450 2A6 and the body status of iron stores in adult Thai males and females. , 2002, Pharmacogenetics.
[101] C. Sweeney,et al. CYP2A6 activity determined by caffeine phenotyping: association with colorectal cancer risk. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[102] Philip Lazarus,et al. Glucuronidation: an important mechanism for detoxification of benzo[a]pyrene metabolites in aerodigestive tract tissues. , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[103] E. Sellers,et al. Gender differences in tobacco smoking: higher relative exposure to smoke than nicotine in women. , 2002, Journal of women's health & gender-based medicine.
[104] D. Balfour. The Neurobiology of Tobacco Dependence: A Commentary , 2002, Respiration.
[105] R. Tyndale,et al. Genetic Variation in CYP2A6-Mediated Nicotine Metabolism Alters Smoking Behavior , 2002, Therapeutic drug monitoring.
[106] E. Perez-stable,et al. Slower metabolism and reduced intake of nicotine from cigarette smoking in Chinese-Americans. , 2002, Journal of the National Cancer Institute.
[107] Jeffrey P. Jones,et al. An in vivo pilot study characterizing the new CYP2A6*7, *8, and *10 alleles. , 2002, Biochemical and biophysical research communications.
[108] J. Pascussi,et al. Transcriptional Regulation of CYP2C9 Gene , 2002, The Journal of Biological Chemistry.
[109] K. Iwahashi,et al. EFFECTS OF WHOLE DELETION OF CYP2A6 ON NICOTINE METABOLISM IN HUMANS , 2002, Drug and chemical toxicology.
[110] M. Nakajima,et al. INTERINDIVIDUAL DIFFERENCES IN NICOTINE METABOLISM AND GENETIC POLYMORPHISMS OF HUMAN CYP2A6 , 2002, Drug metabolism reviews.
[111] Hannu Raunio,et al. Expression and Regulation of Xenobiotic-Metabolizing Cytochrome P450 (CYP) Enzymes in Human Lung , 2002, Critical reviews in toxicology.
[112] J. Pascussi,et al. ROLE OF GLUCOCORTICOID RECEPTOR AND CONSTITUTIVE ANDROSTANE RECEPTOR , 2002 .
[113] H. Yamazaki,et al. Twenty one novel single nucleotide polymorphisms (SNPs) of the CYP2A6 gene in Japanese and Caucasians. , 2002, Drug metabolism and pharmacokinetics.
[114] D. Sparks,et al. The nicotinic acetylcholine receptor, smoking, and Alzheimer's disease. , 2002, Journal of Alzheimer's disease : JAD.
[115] J. Mackay,et al. The Tobacco Atlas , 2002 .
[116] J. Pascussi,et al. Dual effect of dexamethasone on CYP3A4 gene expression in human hepatocytes. Sequential role of glucocorticoid receptor and pregnane X receptor. , 2001, European journal of biochemistry.
[117] N. Benowitz,et al. Deficient C‐oxidation of nicotine continued , 2001, Clinical pharmacology and therapeutics.
[118] W. Henderson,et al. QTc prolongation and drugs , 2001, Clinical pharmacology and therapeutics.
[119] Michael D. Johnson,et al. Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. , 2001, The Journal of pharmacology and experimental therapeutics.
[120] G. Bepler,et al. Comparison of cytochrome P450 2A6 polymorphism frequencies in Caucasians and African-Americans using a new one-step PCR-RFLP genotyping method. , 2001, Toxicology.
[121] J. Pankow. A consideration of the role of gas/particle partitioning in the deposition of nicotine and other tobacco smoke compounds in the respiratory tract. , 2001, Chemical research in toxicology.
[122] O Pelkonen,et al. Polymorphisms of CYP2A6 and its practical consequences. , 2001, British journal of clinical pharmacology.
[123] J. Markowitz,et al. Drug Glucuronidation in Clinical Psychopharmacology , 2001, Journal of clinical psychopharmacology.
[124] J. Gilmore,et al. Identification of a 43-kDa protein in human liver cytosol that binds to the 3'-untranslated region of CYP2A6 mRNA. , 2001, Biochemical pharmacology.
[125] R. Edwards,et al. Relationships between non-occupational cadmium exposure and expression of nine cytochrome P450 forms in human liver and kidney cortex samples. , 2001, Biochemical pharmacology.
[126] I. Phillips,et al. Quantification and cellular localization of expression in human skin of genes encoding flavin-containing monooxygenases and cytochromes P450. , 2001, Biochemical pharmacology.
[127] Y. Moriwaki,et al. Widespread cellular distribution of aldehyde oxidase in human tissues found by immunohistochemistry staining. , 2001, Histology and histopathology.
[128] T. Kamataki,et al. Screening of organosulfur compounds as inhibitors of human CYP2A6. , 2001, Drug metabolism and disposition: the biological fate of chemicals.
[129] M. Ingelman-Sundberg,et al. Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: impairment of its promoter activity. , 2001, Biochemical and biophysical research communications.
[130] T Yamamoto,et al. Nicotine metabolism and CYP2A6 allele frequencies in Koreans. , 2001, Pharmacogenetics.
[131] R. Tyndale,et al. Evaluation of methoxsalen, tranylcypromine, and tryptamine as specific and selective CYP2A6 inhibitors in vitro. , 2001, Drug metabolism and disposition: the biological fate of chemicals.
[132] P. Selby,et al. Heavily Smoking Women Who Cannot Quit in Pregnancy: Evidence of Pharmacokinetic Predisposition , 2001, Therapeutic drug monitoring.
[133] K. Kitagawa,et al. Individual differences in urinary cotinine levels in Japanese smokers: relation to genetic polymorphism of drug-metabolizing enzymes. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[134] S. Hecht,et al. Consumption of watercress fails to alter coumarin metabolism in humans. , 2001, Drug metabolism and disposition: the biological fate of chemicals.
[135] M. Kitagawa,et al. CYP2A6*6, a Novel Polymorphism in Cytochrome P450 2A6, Has a Single Amino Acid Substitution (R128Q) That Inactivates Enzymatic Activity* , 2001, The Journal of Biological Chemistry.
[136] M. Eichelbaum,et al. Cellular localization and regional distribution of CYP2D6 mRNA and protein expression in human brain. , 2001, Pharmacogenetics.
[137] T. Yaksh,et al. A-85380 and epibatidine each interact with disparate spinal nicotinic receptor subtypes to achieve analgesia and nociception. , 2001, The Journal of pharmacology and experimental therapeutics.
[138] R. Tyndale,et al. Variable CYP2A6-mediated nicotine metabolism alters smoking behavior and risk. , 2001, Drug metabolism and disposition: the biological fate of chemicals.
[139] T. Kamataki,et al. A novel single nucleotide polymorphism altering stability and activity of CYP2a6. , 2001, Biochemical and biophysical research communications.
[140] O. Pelkonen,et al. In vitro inhibition of cytochrome P450 enzymes in human liver microsomes by a potent CYP2A6 inhibitor, trans-2-phenylcyclopropylamine (tranylcypromine), and its nonamine analog, cyclopropylbenzene. , 2001, Drug metabolism and disposition: the biological fate of chemicals.
[141] H. Issaq,et al. Nicotine metabolism and CYP2D6 phenotype in smokers. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[142] J. Pascussi,et al. Induction of CYP2C genes in human hepatocytes in primary culture. , 2001, Drug metabolism and disposition: the biological fate of chemicals.
[143] M. Oscarson. Genetic polymorphisms in the cytochrome P450 2A6 (CYP2A6) gene: implications for interindividual differences in nicotine metabolism. , 2001, Drug metabolism and disposition: the biological fate of chemicals.
[144] M. Jarvis,et al. Nicotine yield from machine-smoked cigarettes and nicotine intakes in smokers: evidence from a representative population survey. , 2001, Journal of the National Cancer Institute.
[145] Hiroshi Yamamoto,et al. Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans , 2001, Clinical pharmacology and therapeutics.
[146] A. Hansson,et al. Pharmacokinetics of nicotine in healthy elderly people , 2001, Clinical pharmacology and therapeutics.
[147] N. Benowitz,et al. Trans-3'-hydroxycotinine: disposition kinetics, effects and plasma levels during cigarette smoking. , 2001, British journal of clinical pharmacology.
[148] P. Gow,et al. Neonatal hepatic drug elimination. , 2001, Pharmacology & toxicology.
[149] N. Benowitz,et al. Risks and Benefits of Nicotine to Aid Smoking Cessation in Pregnancy , 2001, Drug safety.
[150] E. Lunell,et al. Pharmacokinetic investigation of a nicotine sublingual tablet , 2001, European Journal of Clinical Pharmacology.
[151] O. Niemelä,et al. Cytochromes P450 2A6, 2E1, and 3A and production of protein-aldehyde adducts in the liver of patients with alcoholic and non-alcoholic liver diseases. , 2000, Journal of hepatology.
[152] J. Pascussi,et al. Dexamethasone enhances constitutive androstane receptor expression in human hepatocytes: consequences on cytochrome P450 gene regulation. , 2000, Molecular pharmacology.
[153] S. Hecht,et al. 2'-Hydroxylation of nicotine by cytochrome P450 2A6 and human liver microsomes: formation of a lung carcinogen precursor. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[154] S. Murphy,et al. O-Glucuronidation of the lung carcinogen 4-(methylnitrosamino)-1- (3-pyridyl)-1-butanol (NNAL) by human UDP-glucuronosyltransferases 2B7 and 1A9. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[155] R. Poland,et al. Effect of cigarette smoking on coumarin metabolism in humans. , 2000, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.
[156] T. Kawamoto,et al. Estrogen activation of the nuclear orphan receptor CAR (constitutive active receptor) in induction of the mouse Cyp2b10 gene. , 2000, Molecular endocrinology.
[157] M. Loriot,et al. Structural characterization of a new variant of the CYP2A6 gene (CYP2A6*1B) apparently diagnosed as heterozygotes of CYP2A6*1A and CYP2A6*4C. , 2000, Pharmacogenetics.
[158] S. Shiffman,et al. A pharmacokinetic crossover study to compare the absorption characteristics of three transdermal nicotine patches , 2000, Pharmacology Biochemistry and Behavior.
[159] O. Pelkonen,et al. CYP2A5/CYP2A6 expression in mouse and human hepatocytes treated with various in vivo inducers. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[160] A. Watt,et al. Determination of the in vitro metabolism of (+)- and (-)-epibatidine. , 2000, Journal of chromatography. A.
[161] R. Tyndale,et al. Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking. , 2000, Molecular pharmacology.
[162] Jun-yan Hong,et al. Human cytochrome P450 CYP2A13: predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. , 2000, Cancer research.
[163] E. Lunell,et al. Pharmacokinetics of nicotine in kidney failure , 2000, Clinical pharmacology and therapeutics.
[164] J. Pascussi,et al. Interleukin-6 negatively regulates the expression of pregnane X receptor and constitutively activated receptor in primary human hepatocytes. , 2000, Biochemical and biophysical research communications.
[165] R. Tyndale,et al. Inhibition of cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smoking , 2000, Clinical pharmacology and therapeutics.
[166] P. Jacob,et al. Clinical pharmacology of oral cotinine. , 2000, Drug and alcohol dependence.
[167] W. Tassaneeyakul,et al. Inhibition selectivity of grapefruit juice components on human cytochromes P450. , 2000, Archives of biochemistry and biophysics.
[168] N. Benowitz,et al. Effects of cigarette smoking and carbon monoxide on nicotine and cotinine metabolism , 2000, Clinical pharmacology and therapeutics.
[169] V. Ganapathy,et al. Structural and functional characteristics and tissue distribution pattern of rat OCTN1, an organic cation transporter, cloned from placenta. , 2000, Biochimica et biophysica acta.
[170] P. Robertson,et al. In vitro inhibition and induction of human hepatic cytochrome P450 enzymes by modafinil. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[171] A. Bienert,et al. Influence of smoking on cotinine and caffeine plasma levels in patients with alcoholic liver cirrhosis. , 2000, European journal of medical research.
[172] L. Moore,et al. Orphan Nuclear Receptors Constitutive Androstane Receptor and Pregnane X Receptor Share Xenobiotic and Steroid Ligands* , 2000, The Journal of Biological Chemistry.
[173] N. Benowitz,et al. Nicotine metabolism and elimination kinetics in newborns , 2000, Clinical pharmacology and therapeutics.
[174] S. Levy,et al. Fatal poisoning from Nicotiana glauca leaves: identification of anabasine by gas-chromatography/mass spectrometry. , 2000, Journal of forensic sciences.
[175] K. Castagnoli,et al. Studies on the in vivo biotransformation of the tobacco alkaloid beta-nicotyrine. , 2000, Chemical research in toxicology.
[176] O. Pelkonen,et al. CYP2A6: a human coumarin 7-hydroxylase. , 2000, Toxicology.
[177] S. Hecht,et al. Enantiomeric composition of N'-nitrosonornicotine and N'-nitrosoanatabine in tobacco. , 2000, Carcinogenesis.
[178] R. West,et al. A comparison of the abuse liability and dependence potential of nicotine patch, gum, spray and inhaler , 2000, Psychopharmacology.
[179] K. Husgafvel‐Pursiainen,et al. CYP2D6 ultrarapid metabolizer genotype as a potential modifier of smoking behaviour. , 2000, Pharmacogenetics.
[180] Hiroshi Yamamoto,et al. Deficient cotinine formation from nicotine is attributed to the whole deletion of the CYP2A6 gene in humans , 2000, Clinical pharmacology and therapeutics.
[181] Y. Berger,et al. Expression and induction of CYP1A1/1A2, CYP2A6 and CYP3A4 in primary cultures of human hepatocytes: a 10-year follow-up , 2000, Xenobiotica; the fate of foreign compounds in biological systems.
[182] N. Benowitz,et al. Nicotine‐mecamylamine interactions , 1999, Clinical pharmacology and therapeutics.
[183] M. Bootman,et al. 13th International Symposium on Microsomes and Drug Oxidations , 2000 .
[184] J. Spence,et al. Pharmacokinetic-Pharmacodynamic Consequences and Clinical Relevance of Cytochrome P450 3A4 Inhibition , 2000, Clinical pharmacokinetics.
[185] Reducing tobacco use: a report of the Surgeon General--executive summary. , 2000, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.
[186] E. Kharasch,et al. Single-dose methoxsalen effects on human cytochrome P-450 2A6 activity. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[187] J. Wahren,et al. Site of nicotine absorption from a vapour inhaler – comparison with cigarette smoking , 2000, European Journal of Clinical Pharmacology.
[188] E. Perez-stable,et al. Ethnic differences in N-glucuronidation of nicotine and cotinine. , 1999, The Journal of pharmacology and experimental therapeutics.
[189] T. Sawada,et al. [Medical therapy in ulcerative colitis]. , 1999, Nihon rinsho. Japanese journal of clinical medicine.
[190] R. Weinshilboum,et al. Human indolethylamine N-methyltransferase: cDNA cloning and expression, gene cloning, and chromosomal localization. , 1999, Genomics.
[191] O Pelkonen,et al. Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism , 1999, FEBS letters.
[192] S. Hecht,et al. Effects of watercress consumption on urinary metabolites of nicotine in smokers. , 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[193] R. Coleman,et al. Arterial nicotine kinetics during cigarette smoking and intravenous nicotine administration: implications for addiction. , 1999, Drug and alcohol dependence.
[194] K. Kitagawa,et al. The significance of the homozygous CYP2A6 deletion on nicotine metabolism: a new genotyping method of CYP2A6 using a single PCR-RFLP. , 1999, Biochemical and biophysical research communications.
[195] T. Kamataki,et al. Homologous unequal cross-over within the human CYP2A gene cluster as a mechanism for the deletion of the entire CYP2A6 gene associated with the poor metabolizer phenotype. , 1999, Journal of biochemistry.
[196] E. Leitner,et al. Determination of the nicotine content of various edible nightshades (Solanaceae) and their products and estimation of the associated dietary nicotine intake. , 1999, Journal of agricultural and food chemistry.
[197] L. Mellick,et al. Neuromuscular blockade after ingestion of tree tobacco (Nicotiana glauca). , 1999, Annals of emergency medicine.
[198] D. Hum,et al. The Monkey and Human Uridine Diphosphate-Glucuronosyltransferase UGT1A9, Expressed in Steroid Target Tissues, Are Estrogen-Conjugating Enzymes. , 1999, Endocrinology.
[199] D. Dempsey,et al. The detection of cotinine in hydrolyzed meconium samples. , 1999, Forensic science international.
[200] S. Anttila,et al. Expression of CYP2A genes in human liver and extrahepatic tissues. , 1999, Biochemical pharmacology.
[201] S. Murphy,et al. Characterization of multiple products of cytochrome P450 2A6-catalyzed cotinine metabolism. , 1999, Chemical research in toxicology.
[202] K. Igarashi,et al. Studies on the pyrrolinone metabolites derived from the tobacco alkaloid 1-methyl-2-(3-pyridinyl)pyrrole (beta-nicotyrine). , 1999, Chemical research in toxicology.
[203] N. Benowitz,et al. Drug Interactions with Tobacco Smoking , 1999, Clinical pharmacokinetics.
[204] P. Beaune,et al. Human CYP2B6: expression, inducibility and catalytic activities. , 1999, Pharmacogenetics.
[205] C. Stockmeier,et al. Increased nicotinic receptors in brains from smokers: membrane binding and autoradiography studies. , 1999, The Journal of pharmacology and experimental therapeutics.
[206] J. Nezu,et al. Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations. , 1999, The Journal of pharmacology and experimental therapeutics.
[207] N. Benowitz,et al. Minor tobacco alkaloids as biomarkers for tobacco use: comparison of users of cigarettes, smokeless tobacco, cigars, and pipes. , 1999, American journal of public health.
[208] K. Bock,et al. Induction of human UDP glucuronosyltransferases (UGT1A6, UGT1A9, and UGT2B7) by t-butylhydroquinone and 2,3,7,8-tetrachlorodibenzo-p-dioxin in Caco-2 cells. , 1999, Drug metabolism and disposition: the biological fate of chemicals.
[209] M. Ingelman-Sundberg,et al. Characterisation and PCR‐based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population , 1999, FEBS letters.
[210] D. Beckers,et al. Cotinine in meconium indicates risk for early respiratory tract infections , 1999, Human & experimental toxicology.
[211] T. Kamataki,et al. A new CYP2A6 gene deletion responsible for the in vivo polymorphic metabolism of (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride in humans. , 1999, The Journal of pharmacology and experimental therapeutics.
[212] Kiyoshi Inoue,et al. Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes , 1999, Archives of Toxicology.
[213] M. Manns,et al. Regulation and function of family 1 and family 2 UDP-glucuronosyltransferase genes (UGT1A, UGT2B) in human oesophagus. , 1999, The Biochemical journal.
[214] D. N. Sims,et al. Another death due to ingestion of Nicotiana glauca. , 1999, Journal of forensic sciences.
[215] D. Hatsukami,et al. Quantitation of urinary metabolites of a tobacco-specific lung carcinogen after smoking cessation. , 1999, Cancer research.
[216] C. Wild,et al. Characterization of cytochrome P450 expression in human oesophageal mucosa. , 1999, Carcinogenesis.
[217] D. Hatsukami,et al. Quantitation of 4-oxo-4-(3-pyridyl)butanoic acid and enantiomers of 4-hydroxy-4-(3-pyridyl)butanoic acid in human urine: A substantial pathway of nicotine metabolism. , 1999, Chemical research in toxicology.
[218] J. Andre,et al. Metabolism and disposition of GTS-21, a novel drug for Alzheimer's disease. , 1999, Xenobiotica; the fate of foreign compounds in biological systems.
[219] D. Armstrong,et al. Enantiomeric composition of nornicotine, anatabine, and anabasine in tobacco , 1999 .
[220] S. Arneric,et al. Neuronal nicotinic receptors : pharmacology and therapeutic opportunities , 1999 .
[221] M. Tsai,et al. EVIDENCE FOR THE BIOSYNTHESIS OF A GLUCURONIDE CONJUGATE OF (S)-(-)-NICOTINE, BUT NOT (SM-)-COTININE OR (±)-trans-3'- HYDROXYCOTININE BY MARMOSET HEPATIC MICROSOMES , 1999, Drug metabolism and drug interactions.
[222] J. I. Seeman,et al. 5'-hydroxycotinine-N-oxide, a new nicotine metabolite isolated from rat urine. , 1999, Xenobiotica; the fate of foreign compounds in biological systems.
[223] R. Koeppe,et al. Arterial/venous plasma nicotine concentrations following nicotine nasal spray , 1999, European Journal of Clinical Pharmacology.
[224] L. Kozlowski,et al. Filter ventilation and nicotine content of tobacco in cigarettes from Canada, the United Kingdom, and the United States , 1998, Tobacco control.
[225] G. Koren,et al. Transplacental transfer and biotransformation studies of nicotine in the human placental cotyledon perfused in vitro. , 1998, Life sciences.
[226] S. Masuda,et al. Functional characteristics and membrane localization of rat multispecific organic cation transporters, OCT1 and OCT2, mediating tubular secretion of cationic drugs. , 1998, The Journal of pharmacology and experimental therapeutics.
[227] W. Thilly,et al. Measurement of cytochrome P450 2A6 and 2E1 gene expression in primary human bronchial epithelial cells. , 1998, Carcinogenesis.
[228] D. G. McCarver,et al. A genetic polymorphism in the regulatory sequences of human CYP2E1: association with increased chlorzoxazone hydroxylation in the presence of obesity and ethanol intake. , 1998, Toxicology and applied pharmacology.
[229] D. Altman,et al. Green tobacco sickness , 1998, Tobacco control.
[230] T. Rao,et al. Conformationally restricted analogues of nicotine and anabasine. , 1998, Bioorganic & medicinal chemistry letters.
[231] L. Palmer,et al. The elimination half-life of urinary cotinine in children of tobacco-smoking mothers. , 1998, Pulmonary pharmacology & therapeutics.
[232] M. Takano,et al. Distinct characteristics of transcellular transport between nicotine and tetraethylammonium in LLC-PK1 cells. , 1998, The Journal of pharmacology and experimental therapeutics.
[233] E. Perez-stable,et al. Nicotine metabolism and intake in black and white smokers. , 1998, JAMA.
[234] G. Giovino,et al. Racial and ethnic differences in serum cotinine levels of cigarette smokers: Third National Health and Nutrition Examination Survey, 1988-1991. , 1998, JAMA.
[235] D. Hatsukami,et al. Effects of cotinine on cigarette self-administration , 1998, Psychopharmacology.
[236] E. Perry,et al. Dopamine and nicotinic receptor binding and the levels of dopamine and homovanillic acid in human brain related to tobacco use , 1998, Neuroscience.
[237] E. Richter,et al. Occurrence of the Tobacco Alkaloid Myosmine in Nuts and Nut Products of Arachus hypogaea and Corylus avellana , 1998 .
[238] S. Hecht,et al. Biochemistry, biology, and carcinogenicity of tobacco-specific N-nitrosamines. , 1998, Chemical research in toxicology.
[239] Y. Funae,et al. A new deleted allele in the human cytochrome P450 2A6 (CYP2A6) gene found in individuals showing poor metabolic capacity to coumarin and (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride (SM-12502). , 1998, Pharmacogenetics.
[240] G. Hageman,et al. Analysis of urinary caffeine metabolites to assess biotransformation enzyme activities by reversed-phase high-performance liquid chromatography. , 1998, Journal of chromatography. B, Biomedical sciences and applications.
[241] I. Baranowska,et al. Determination of nicotine, cotinine and caffeine in meconium using high-performance liquid chromatography. , 1998, Journal of chromatography. B, Biomedical sciences and applications.
[242] M. Manns,et al. Expression of the UDP-glucuronosyltransferase 1A Locus in Human Colon , 1998, The Journal of Biological Chemistry.
[243] B. Burchell,et al. Drug glucuronidation by human renal UDP-glucuronosyltransferases. , 1998, Biochemical pharmacology.
[244] M. Jarvis,et al. Variations in cotinine levels in smokers during and after pregnancy. , 1998, American journal of obstetrics and gynecology.
[245] J. Gustafsson,et al. Characterization of cytochrome P450 enzymes in human breast tissue from reduction mammaplasties. , 1998, The Journal of clinical endocrinology and metabolism.
[246] B. Ludes,et al. Nicotine monitoring in sweat with a sweat patch. , 1998, Journal of chromatography. B, Biomedical sciences and applications.
[247] D. Hatsukami,et al. Cotinine: effects with and without nicotine , 1998, Psychopharmacology.
[248] Y. Soini,et al. Cytochrome P4502A6 (CYP2A6) expression in human hepatocellular carcinoma , 1998, Hepatology.
[249] D. Donnelly-roberts,et al. Broad-spectrum, non-opioid analgesic activity by selective modulation of neuronal nicotinic acetylcholine receptors. , 1998, Science.
[250] S. Ralapati,et al. Application of high‐performance capillary electrophoresis to the quantitative analysis of nicotine and profiling of other alkaloids in ATF‐regulated tobacco products , 1998, Electrophoresis.
[251] D. Armstrong,et al. Enantiomeric Composition of Nicotine in Smokeless Tobacco, Medicinal Products, and Commercial Reagents , 1998 .
[252] E. Callaway,et al. Effects of cotinine on information processing in nonsmokers , 1998, Psychopharmacology.
[253] J K Lynch,et al. Neuronal nicotinic acetylcholine receptors as targets for drug discovery. , 1997, Journal of medicinal chemistry.
[254] O. Pelkonen,et al. Hepatitis A impairs the function of human hepatic CYP2A6 in vivo. , 1997, Toxicology.
[255] K. Ahijevych,et al. Nicotine dependence and smoking topography among black and white women. , 1997, Research in nursing & health.
[256] W. Trager,et al. Mechanism-based inactivation of human liver cytochrome P450 2A6 by 8-methoxypsoralen. , 1997, Drug metabolism and disposition: the biological fate of chemicals.
[257] S. Imaoka,et al. A comparison of hepatic cytochrome P450 protein expression between infancy and postinfancy. , 1997, Life sciences.
[258] A. Li,et al. Quantitative reverse transcriptase/PCR assay for the measurement of induction in cultured hepatocytes. , 1997, Chemico-biological interactions.
[259] N. Benowitz,et al. Arteriovenous differences in plasma concentration of nicotine and catecholamines and related cardiovascular effects after smoking, nicotine nasal spray, and intravenous nicotine , 1997, Clinical pharmacology and therapeutics.
[260] A. Zinsmeister,et al. A dose‐ranging pharmacokinetic study of nicotine tartrate following single‐dose delayed‐release oral and intravenous administration , 1997, Alimentary pharmacology & therapeutics.
[261] N. Chauret,et al. In vitro comparison of cytochrome P450-mediated metabolic activities in human, dog, cat, and horse. , 1997, Drug metabolism and disposition: the biological fate of chemicals.
[262] D. Donnelly-roberts,et al. ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine]: I. A potent and selective cholinergic channel modulator with neuroprotective properties. , 1997, The Journal of pharmacology and experimental therapeutics.
[263] R. Tyndale,et al. A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. , 1997, The Journal of pharmacology and experimental therapeutics.
[264] J. Idle,et al. A single amino acid substitution (Leu160His) in cytochrome P450 CYP2A6 causes switching from 7-hydroxylation to 3-hydroxylation of coumarin. , 1997, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.
[265] D. Hatsukami,et al. Safety of Cotinine in Humans: Physiologic, Subjective, and Cognitive Effects , 1997, Pharmacology Biochemistry and Behavior.
[266] P. Kemp,et al. Postmortem distribution of nicotine and cotinine from a case involving the simultaneous administration of multiple nicotine transdermal systems. , 1997, Journal of analytical toxicology.
[267] E. London,et al. [125I]IPH, an epibatidine analog, binds with high affinity to neuronal nicotinic cholinergic receptors. , 1997, The Journal of pharmacology and experimental therapeutics.
[268] A. C. Collins,et al. Effect of Smoking History on [ 3 H]nicotine Binding in Human Postmortem Brain 1 , 2022 .
[269] N. Benowitz,et al. Cotinine effects on nicotine metabolism , 1997, Clinical pharmacology and therapeutics.
[270] A. Zinsmeister,et al. Pharmacokinetics of Nicotine Tartrate after Single‐Dose Liquid Enema, Oral, and Intravenous Administration , 1997, Journal of clinical pharmacology.
[271] G. Andersson,et al. The influence of cigarette consumption and smoking machine yields of tar and nicotine on the nicotine uptake and oral mucosal lesions in smokers. , 1997, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.
[272] D. Desai,et al. Evidence for endogenous formation of tobacco-specific nitrosamines in rats treated with tobacco alkaloids and sodium nitrite. , 1997, Carcinogenesis.
[273] D. Hatsukami,et al. Society for Research on Nicotine and Tobacco. , 1997, Addiction.
[274] W. Legrum,et al. The character of inhibition of the metabolism of 1,2-benzopyrone (coumarin) by grapefruit juice in human , 1997, European Journal of Clinical Pharmacology.
[275] T. Rao,et al. Effects of a novel cholinergic ion channel agonist SIB-1765F on locomotor activity in rats. , 1997, The Journal of pharmacology and experimental therapeutics.
[276] M. Bencherif,et al. RJR-2403: a nicotinic agonist with CNS selectivity I. In vitro characterization. , 1996, The Journal of pharmacology and experimental therapeutics.
[277] Y. Funae,et al. Role of human cytochrome P4502A6 in C-oxidation of nicotine. , 1996, Drug metabolism and disposition: the biological fate of chemicals.
[278] S. Kitamura,et al. S‐(‐)‐nicotine‐1′‐N‐oxide reductase activity of rat liver aldehyde oxidase , 1996, Biochemistry and molecular biology international.
[279] D Verotta,et al. Chronopharmacokinetics of nicotine , 1996, Clinical pharmacology and therapeutics.
[280] H. Bartsch,et al. Induction of cytochrome P450 2A6 expression in humans by the carcinogenic parasite infection, opisthorchiasis viverrini. , 1996, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[281] R. Olmstead,et al. Efficacy of a nicotine inhaler in smoking cessation: a double-blind, placebo-controlled trial. , 1996, Addiction.
[282] P. Adams,et al. (S)-(-)-5-ethynyl-3-(1-methyl-2-pyrrolidinyl)pyridine maleate (SIB-1508Y): a novel anti-parkinsonian agent with selectivity for neuronal nicotinic acetylcholine receptors. , 1996, Journal of medicinal chemistry.
[283] A. Rautio,et al. Age and CYP3A4 and CYP2A6 activities marked by the metabolism of lignocaine and coumarin in man. , 1996, Therapie.
[284] N. Benowitz,et al. The Benefits of Stopping Smoking and the Role of Nicotine Replacement Therapy in Older Patients , 1996, Drugs & aging.
[285] G. Batist,et al. Overexpression of Cytochrome P-450 Isoforms Involved in Aflatoxin B1 Bioactivation in Human Liver with Cirrhosis and Hepatitis , 1996, Toxicologic pathology.
[286] E. Perez-stable,et al. CYP2D6 phenotype and the metabolism of nicotine and cotinine. , 1996, Pharmacogenetics.
[287] Y. Funae,et al. Characterization of CYP2A6 involved in 3'-hydroxylation of cotinine in human liver microsomes. , 1996, The Journal of pharmacology and experimental therapeutics.
[288] A. Nordberg,et al. Nicotine deposition and body distribution from a nicotine inhaler and a cigarette studied with positron emission tomography , 1996, Clinical pharmacology and therapeutics.
[289] E. Lunell,et al. Dose released and absolute bioavailability of nicotine from a nicotine vapor inhaler , 1996, Clinical pharmacology and therapeutics.
[290] Y. Berger,et al. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. , 1996, The Journal of pharmacology and experimental therapeutics.
[291] N. Benowitz,et al. Cotinine as a biomarker of environmental tobacco smoke exposure. , 1996, Epidemiologic reviews.
[292] H. Yamazaki,et al. Ethnic-related differences in coumarin 7-hydroxylation activities catalyzed by cytochrome P4502A6 in liver microsomes of Japanese and Caucasian populations. , 1996, Xenobiotica; the fate of foreign compounds in biological systems.
[293] N. Benowitz. Pharmacology of nicotine: addiction and therapeutics. , 1996, Annual review of pharmacology and toxicology.
[294] O. Pelkonen,et al. Coumarin 7-hydroxylation in long-term adherents of a strict uncooked vegan diet , 1996, European Journal of Clinical Pharmacology.
[295] E. Lunell,et al. Transdermally administered nicotine accumulates in gastric juice , 1996, European Journal of Clinical Pharmacology.
[296] M. Jarvik,et al. Efficacy of a nicotine nasal spray in smoking cessation: a placebo-controlled, double-blind trial. , 1995, Addiction.
[297] A. D. Rodrigues,et al. In vitro hepatic metabolism of ABT-418 in chimpanzee (Pan troglodytes). A unique pattern of microsomal flavin-containing monooxygenase-dependent stereoselective N'-oxidation. , 1995, Drug metabolism and disposition: the biological fate of chemicals.
[298] S. Wrighton,et al. In vitro-in vivo correlations of human (S)-nicotine metabolism. , 1995, Biochemical pharmacology.
[299] S. Arneric,et al. Characterization of [3H]ABT-418: a novel cholinergic channel ligand. , 1995, The Journal of pharmacology and experimental therapeutics.
[300] N. Benowitz,et al. Deficient C‐oxidation of nicotine , 1995, Clinical pharmacology and therapeutics.
[301] S. Balabanova,et al. [Detection of nicotine in eccrine sweat after stimulation of sweat glands during nicotine withdrawal]. , 1995, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.
[302] A. Nordberg,et al. Regional deposition of inhaled 11C‐nicotine vapor in the human airway as visualized by positron emission tomography , 1995, Clinical pharmacology and therapeutics.
[303] S. Skerfving,et al. Urinary cotinine in children and adults during and after semiexperimental exposure to environmental tobacco smoke. , 1995, Archives of environmental health.
[304] D. Madlon-Kay. Transdermal Nicotine Patches , 1995, The Journal of the American Board of Family Medicine.
[305] N. Benowitz. Clinical pharmacology of transdermal nicotine , 1995 .
[306] O. Pelkonen,et al. CYP3A4 and CYP2A6 activities marked by the metabolism of lignocaine and coumarin in patients with liver and kidney diseases and epileptic patients. , 1995, British journal of clinical pharmacology.
[307] P. Clarke,et al. Effects of Nicotine on Biological Systems II , 1995, Advances in Pharmacological Sciences.
[308] N. Benowitz,et al. Metabolism of nicotine to cotinine studied by a dual stable isotope method , 1994, Clinical pharmacology and therapeutics.
[309] A. M. Collier,et al. Cotinine Elimination and Its Use as a Biomarker in Young Children Involuntarily Exposed to Environmental Tobacco Smoke , 1994 .
[310] O Pelkonen,et al. Metabolic interactions of methoxsalen and coumarin in humans and mice. , 1994, Biochemical pharmacology.
[311] F. Guengerich,et al. Metabolic activation and carcinogen-DNA adduct detection in human larynx. , 1994, Cancer research.
[312] A. D. Rodrigues,et al. The in vitro hepatic metabolism of ABT-418, a cholinergic channel activator, in rats, dogs, cynomolgus monkeys, and humans. , 1994, Drug metabolism and disposition: the biological fate of chemicals.
[313] B. Eskenazi,et al. Black-white differences in serum cotinine levels among pregnant women and subsequent effects on infant birthweight. , 1994, American journal of public health.
[314] H. Yamazaki,et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. , 1994, The Journal of pharmacology and experimental therapeutics.
[315] D. Hatsukami,et al. Pharmacodynamic effects of cotinine in abstinent cigarette smokers , 1994, Clinical pharmacology and therapeutics.
[316] K. Tilashalski,et al. Assessing the nicotine content of smokeless tobacco products. , 1994, Journal of the American Dental Association.
[317] E. Ostrea,et al. Meconium analysis to assess fetal exposure to nicotine by active and passive maternal smoking. , 1994, The Journal of pediatrics.
[318] R. Hurt,et al. Nicotine patch therapy for smoking cessation combined with physician advice and nurse follow-up. One-year outcome and percentage of nicotine replacement. , 1994, JAMA.
[319] W. S. Caldwell,et al. Direct determination of cotinine-N-glucuronide in urine using thermospray liquid chromatography/mass spectrometry. , 1994, Biological mass spectrometry.
[320] N. Benowitz,et al. Nicotine metabolic profile in man: comparison of cigarette smoking and transdermal nicotine. , 1994, The Journal of pharmacology and experimental therapeutics.
[321] Y. Li,et al. N-hydroxymethylnorcotinine, a new primary in vitro metabolite of cotinine. , 1994, Xenobiotica; the fate of foreign compounds in biological systems.
[322] N. Benowitz,et al. Stereoselective metabolism of (S)-(-)-nicotine in humans: formation of trans-(S)-(-)-nicotine N-1'-oxide. , 1993, Chemical research in toxicology.
[323] E. Vesell,et al. Identification of radiolabeled metabolites of nicotine in rat bile. Synthesis of S-(-)-nicotine N-glucuronide and direct separation of nicotine-derived conjugates using high-performance liquid chromatography. , 1993, Journal of chromatography.
[324] J. Henningfield,et al. Nicotine delivery kinetics and abuse liability. , 1993, Journal of consulting and clinical psychology.
[325] E. Domino,et al. The nicotine content of common vegetables. , 1993, The New England journal of medicine.
[326] Richard D. Prather,et al. Nicotine Pharmacokinetics of Nicoderm® (Nicotine Transdermal System) in Women and Obese Men Compared With Normal‐Sized Men , 1993, Journal of clinical pharmacology.
[327] Imaoka Susumu,et al. Nicotine metabolism by rat hepatic cytochrome P450s , 1993 .
[328] J E Henningfield,et al. Higher levels of nicotine in arterial than in venous blood after cigarette smoking. , 1993, Drug and alcohol dependence.
[329] E. Nexo,et al. Acute effects of smoking during modified sham feeding in duodenal ulcer patients. An analysis of nicotine, acid secretion, gastrin, catecholamines, epidermal growth factor, prostaglandin E2, and bile acids. , 1993, Scandinavian journal of gastroenterology.
[330] D. Sparks,et al. Immunohistochemical Localization of a Cytochrome P-450 Isozyme in Human Nasal Mucosa: Age-Related Trends , 1993, The Annals of otology, rhinology, and laryngology.
[331] N. Benowitz,et al. Nicotine and cotinine elimination pharmacokinetics in smokers and nonsmokers , 1993, Clinical pharmacology and therapeutics.
[332] K. Vähäkangas,et al. Extrahepatic metabolism of nicotine and related compounds by cytochromes P450 , 1993 .
[333] J. Wahren,et al. Nicotine and related alkaloids : absorption, distribution, metabolism, and excretion , 1993 .
[334] Felix Franks,et al. In-Vitro Characterization of mCerulean3_mRuby3 as a Novel FRET Pair with Favorable Bleed-Through Characteristics , 2019, Biosensors.
[335] N. Castagnoli,et al. The metabolic fate of the minor tobacco alkaloids , 1993 .
[336] Smoking cessation during previous year among adults--United States, 1990 and 1991. , 1993, MMWR. Morbidity and mortality weekly report.
[337] E. Vesell,et al. Variables affecting nicotine metabolism. , 1993, Pharmacology & therapeutics.
[338] S. Imaoka,et al. Nicotine metabolism by rat hepatic cytochrome P450s. , 1993, Biochemical pharmacology.
[339] A. Parkinson,et al. Species differences and interindividual variation in liver microsomal cytochrome P450 2A enzymes: effects on coumarin, dicumarol, and testosterone oxidation. , 1992, Archives of biochemistry and biophysics.
[340] O Pelkonen,et al. Interindividual variability of coumarin 7-hydroxylation in healthy volunteers. , 1992, Pharmacogenetics.
[341] N. Benowitz,et al. Metabolism of nicotine by human liver microsomes: stereoselective formation of trans-nicotine N'-oxide. , 1992, Chemical research in toxicology.
[342] S. Davies,et al. Localization of cytochrome P‐450 gene expression in normal and diseased human liver by in situ hybridization of wax‐embedded archival material , 1992, Hepatology.
[343] Alan D. Lopez,et al. Mortality from tobacco in developed countries: indirect estimation from national vital statistics , 1992, The Lancet.
[344] G. Byrd,et al. Evidence for urinary excretion of glucuronide conjugates of nicotine, cotinine, and trans-3'-hydroxycotinine in smokers. , 1992, Drug metabolism and disposition: the biological fate of chemicals.
[345] C. Bonfils,et al. Purification of two cytochrome P450 isozymes related to CYP2A and CYP3A gene families from monkey (baboon, Papio papio) liver microsomes. Cross reactivity with human forms. , 1992, European journal of biochemistry.
[346] P. Crooks,et al. Characterization of the glucuronide conjugate of cotinine: a previously unidentified major metabolite of nicotine in smokers' urine. , 1992, Chemical research in toxicology.
[347] S Balabanova,et al. [Nicotine excretion by the apocrine and eccrine sweat in smokers and passive smokers]. , 1992, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.
[348] T. Aoyama,et al. Nicotine metabolism by cDNA-expressed human cytochrome P-450s , 1992 .
[349] P. Crooks,et al. Inhibition of [3H]dopamine uptake into rat striatal slices by quaternary N-methylated nicotine metabolites. , 1992, Life sciences.
[350] S. Pelletier. Alkaloids: Chemical and Biological Perspectives , 1992, Alkaloids: Chemical and Biological Perspectives.
[351] S. Emiliani,et al. Isolation and characterization of a cytochrome P450 of the IIA subfamily from human liver microsomes. , 1991, European journal of biochemistry.
[352] E. Vesell,et al. Nicotine metabolism in stumptailed macaques, Macaca arctoides. , 1991, Drug metabolism and disposition: the biological fate of chemicals.
[353] D. Hammond,et al. Metabolism of nicotine by rat liver cytochromes P-450. Assessment utilizing monoclonal antibodies to nicotine and cotinine. , 1991, Drug metabolism and disposition: the biological fate of chemicals.
[354] N. Benowitz,et al. Stable isotope studies of nicotine kinetics and bioavailability , 1991, Clinical pharmacology and therapeutics.
[355] D. Bailey,et al. Interaction of citrus juices with felodipine and nifedipine , 1991, The Lancet.
[356] G. Englund,et al. Conjugation Pathways in Nicotine Metabolism , 1991 .
[357] Neurath Gb,et al. Detection of Nornicotine in Human Urine after Infusion of Nicotine , 1991 .
[358] N. Benowitz,et al. Oxidative Metabolism of Nicotine In Vivo , 1991 .
[359] S. Kira,et al. Respiratory nicotine absorption in non-smoking females during passive smoking , 1991, International archives of occupational and environmental health.
[360] E. Vesell,et al. Disposition of nicotine and eight metabolites in smokers and nonsmokers: Identification in smokers of two metabolites that are longer lived than cotinine , 1990, Clinical pharmacology and therapeutics.
[361] E. Vesell,et al. Metabolism of nicotine by hepatocytes. , 1990, Biochemical pharmacology.
[362] N. Benowitz,et al. Synthesis of (3'R,5'S)-trans-3'-hydroxycotinine, a major metabolite of nicotine. Metabolic formation of 3'-hydroxycotinine in humans is highly stereoselective. , 1990, Journal of medicinal chemistry.
[363] R. Obach,et al. Radioimmunoassay of nicotine-delta 1'(5')-iminium ion, an intermediate formed during the metabolism of nicotine to cotinine. , 1990, Drug metabolism and disposition: the biological fate of chemicals.
[364] D. Williams,et al. The role of cytochromes P-450 and flavin-containing monooxygenase in the metabolism of (S)-nicotine by rabbit lung. , 1990, Drug metabolism and disposition: the biological fate of chemicals.
[365] F. Gonzalez,et al. The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. , 1990, Biochemistry.
[366] B. Lundell,et al. Nicotine and Cotinine Concentrations in the Nursing Mother and Her Infant , 1990, Acta paediatrica Scandinavica.
[367] M. J. Coon,et al. Rabbit nasal cytochrome P-450 NMa has high activity as a nicotine oxidase. , 1990, Biochemical and biophysical research communications.
[368] I. Stolerman,et al. Nicotine psychopharmacology : molecular, cellular, and behavioural aspects , 1990 .
[369] N. Benowitz. Clinical pharmacology of inhaled drugs of abuse: implications in understanding nicotine dependence. , 1990, NIDA research monograph.
[370] D. Jacobs,et al. Racial differences in serum cotinine levels among smokers in the Coronary Artery Risk Development in (Young) Adults study. , 1990, American journal of public health.
[371] S. Balabanova,et al. [Detection of drugs in sweat]. , 1990, Beitrage zur gerichtlichen Medizin.
[372] K. Rustemeier,et al. Identification of cis-3'-hydroxycotinine as a urinary nicotine metabolite. , 1990, Xenobiotica; the fate of foreign compounds in biological systems.
[373] P. Jacob,et al. Liver and lung microsomal metabolism of the tobacco alkaloid beta-nicotyrine. , 1989, Chemical research in toxicology.
[374] M. Jarvik,et al. Food and nicotine metabolism , 1989, Pharmacology Biochemistry and Behavior.
[375] D Hoffmann,et al. The relevance of tobacco-specific nitrosamines to human cancer. , 1989, Cancer surveys.
[376] N. Benowitz,et al. Nicotine absorption and cardiovascular effects with smokeless tobacco use: Comparison with cigarettes and nicotine gum , 1988, Clinical pharmacology and therapeutics.
[377] M. Shigenaga,et al. Metabolism-dependent covalent binding of (S)-[5-3H]nicotine to liver and lung microsomal macromolecules. , 1988, Drug metabolism and disposition: the biological fate of chemicals.
[378] M. Benwell,et al. Evidence that Tobacco Smoking Increases the Density of (−)‐[3H]Nicotine Binding Sites in Human Brain , 1988, Journal of neurochemistry.
[379] P. Crooks,et al. N‐Methylation of nicotine enantiomers by human liver cytosol , 1988, The Journal of pharmacy and pharmacology.
[380] P. Crooks,et al. Species variation and stereoselectivity in the metabolism of nicotine enantiomers. , 1988, Xenobiotica; the fate of foreign compounds in biological systems.
[381] M. Verstraete. Neuere Etnwicklungen in der Fibrinolyse , 1988 .
[382] G. Neurath,et al. Trans-3'-hydroxycotinine--a main metabolite in smokers. , 1988, Klinische Wochenschrift.
[383] H. Muranaka,et al. Evaluation of nicotine, cotinine, thiocyanate, carboxyhemoglobin, and expired carbon monoxide as biochemical tobacco smoke uptake parameters , 1988, International archives of occupational and environmental health.
[384] L. Jarczyk,et al. Pharmacokinetics of nicotine, cotinine, and 3'-hydroxycotinine in cigarette smokers. , 1988, Klinische Wochenschrift.
[385] J. Palca. Nicotine addiction , 1988, Nature.
[386] N. Benowitz,et al. Apparent tolerance to the acute effect of nicotine results in part from distribution kinetics. , 1987, The Journal of clinical investigation.
[387] N. Benowitz,et al. Influence of tobacco abstinence on the disposition kinetics and effects of nicotine , 1987, Clinical pharmacology and therapeutics.
[388] N. Benowitz,et al. Determinants of nicotine intake while chewing nicotine polacrilex gum , 1987, Clinical pharmacology and therapeutics.
[389] L. Peterson,et al. Stereochemical studies on the cytochrome P-450 catalyzed oxidation of (S)-nicotine to the (S)-nicotine delta 1'(5')-iminium species. , 1987, Journal of medicinal chemistry.
[390] G. Neurath,et al. Trans-3′-hydroxycotinine as a main metabolite in urine of smokers , 1987, International archives of occupational and environmental health.
[391] N. Benowitz,et al. Identification and quantitative analysis of cotinine-N-oxide in human urine. , 1987, Journal of chromatography.
[392] J. Garriott,et al. A fatal poisoning from Nicotiana glauca. , 1987, Journal of toxicology. Clinical toxicology.
[393] G. B. Gori,et al. Mouth versus deep airways absorption of nicotine in cigarette smokers , 1986, Pharmacology Biochemistry and Behavior.
[394] G. B. Gori,et al. Analytical cigarette yields as predictors of smoke bioavailability. , 1985, Regulatory toxicology and pharmacology : RTP.
[395] N. Benowitz,et al. Nicotine renal excretion rate influences nicotine intake during cigarette smoking. , 1985, The Journal of pharmacology and experimental therapeutics.
[396] R. Etzel,et al. Urine cotinine excretion in neonates exposed to tobacco smoke products in utero. , 1985, The Journal of pediatrics.
[397] M. Noma,et al. The alkaloid contents of sixty Nicotiana species , 1985 .
[398] O. Pelkonen,et al. Coumarin 7-hydroxylase activity in human liver microsomes. Properties of the enzyme and interspecies comparisons. , 1985, British journal of clinical pharmacology.
[399] H Nau,et al. Extent of nicotine and cotinine transfer to the human fetus, placenta and amniotic fluid of smoking mothers. , 1985, Developmental pharmacology and therapeutics.
[400] M. McNabb. Chewing nicotine gum for 3 months: what happens to plasma nicotine levels? , 1984, Canadian Medical Association journal.
[401] H Nau,et al. Nicotine and cotinine concentrations in serum and milk of nursing smokers. , 1984, British journal of clinical pharmacology.
[402] J. Boreham,et al. Urinary nicotine concentrations in cigarette and pipe smokers. , 1984, Thorax.
[403] N. Benowitz,et al. Daily intake of nicotine during cigarette smoking , 1984, Clinical pharmacology and therapeutics.
[404] R. Solomon,et al. Elevated nicotine levels in patients undergoing hemodialysis. A role in cardiovascular mortality and morbidity? , 1984, American Journal of Medicine.
[405] N. Benowitz,et al. Cotinine disposition and effects , 1983, Clinical pharmacology and therapeutics.
[406] R. Herning,et al. Smokers of low-yield cigarettes do not consume less nicotine. , 1983, The New England journal of medicine.
[407] N. Benowitz,et al. Circadian blood nicotine concentrations during cigarette smoking , 1982, Clinical pharmacology and therapeutics.
[408] P. Slanina,et al. Nicotyrine inhibits in vivo metabolism of nicotine without increasing its toxicity. , 1982, Toxicology and applied pharmacology.
[409] R. Ebert,et al. Plasma nicotine levels produced by chewing nicotine gum. , 1982, JAMA.
[410] K. McCusker,et al. Plasma nicotine levels in pipe smokers. , 1982, JAMA.
[411] R T Jones,et al. Interindividual variability in the metabolism and cardiovascular effects of nicotine in man. , 1982, The Journal of pharmacology and experimental therapeutics.
[412] J. Gorrod,et al. The metabolism of nicotine-delta 1'(5')-iminium ion, in vivo and in vitro. , 1982, European journal of drug metabolism and pharmacokinetics.
[413] H. Schievelbein. Nicotine, resorption and fate. , 1982, Pharmacology & therapeutics.
[414] N. Wald,et al. SERUM COTININE LEVELS IN PIPE SMOKERS: EVIDENCE AGAINST NICOTINE AS CAUSE OF CORONARY HEART DISEASE , 1981, The Lancet.
[415] H. Ar,et al. Nicotine delta 1 "(5)' iminium ion: a reactive intermediate in nicotine metabolism. , 1981 .
[416] J. Gorrod,et al. Nicotine delta 1 "(5)' iminium ion: a reactive intermediate in nicotine metabolism. , 1981, Advances in experimental medicine and biology.
[417] M A Russell,et al. Relation of nicotine yield of cigarettes to blood nicotine concentrations in smokers. , 1980, British medical journal.
[418] L. Lindblom,et al. The enzyme “aldehyde oxidase” is an iminium oxidase. Reaction with nicotine Δ1′(5′) iminium ion , 1979 .
[419] L. Lindblom,et al. SYNTHESIS, STRUCTURE AND STABILITY OF NICOTINE Δ1′(5′) IMINIUM ION, AN INTERMEDIARY METABOLITE OF NICOTINE , 1979 .
[420] K. Lempert,et al. Synthesis, Structure and Stability of Nicotine Delta1'(5') Iminium Ion, an Intermediary Metabolite of Nicotine. , 1979 .
[421] L. Gruenke,et al. Metabolic oxidation of nicotine to chemically reactive intermediates. , 1979, Journal of medicinal chemistry.
[422] L. Lindblom,et al. The enzyme "aldehyde oxidase" is an iminium oxidase. Reaction with nicotine delta 1'(5') iminium ion. , 1979, Biochemical and biophysical research communications.
[423] C. Dollery,et al. Absorption of nicotine from small cigars , 1978, Clinical pharmacology and therapeutics.
[424] R. Scheline. Mammalian metabolism of plant xenobiotics , 1978 .
[425] C. Feyerabend,et al. Cigarette smoking: a dependence on high-nicotine boli. , 1978, Drug metabolism reviews.
[426] M. Mcnicol,et al. Effect of cigar smoking on carboxyhaemoglobin and plasma nicotine concentrations in primary pipe and cigar smokers and ex-cigarette smokers , 1977, British medical journal.
[427] E. Bowman,et al. The interrelationship between the metabolism of (S)-continine-N-oxide and (S)-cotinine. , 1977, Drug metabolism and disposition: the biological fate of chemicals.
[428] D. Hoffmann,et al. Nitrogen-containing compounds in tobacco and tobacco smoke. , 1977 .
[429] S. Soloway. Naturally occurring insecticides. , 1976, Environmental health perspectives.
[430] A. Poole,et al. The metabolism of (14C)nicotine by isolated rhesus monkey hepatocytes in vitro. , 1976, Biochemical pharmacology.
[431] C. Dollery,et al. Absorption and metabolism of nicotine from cigarettes. , 1975, British medical journal.
[432] A. Beckett,et al. Reduction in vivo of (−)-nicotine-1′-N-oxide by germ-free and conventional rats , 1975 .
[433] P. Jenner,et al. The metabolism of tobacco alkaloids , 1975 .
[434] A. Beckett,et al. Reduction in vivo of (minus)-nicotine-1'-N-oxide by germ-free and conventional rats. , 1975, Biochemical pharmacology.
[435] H. Harke,et al. Demethylation of nicotine and cotinine in pigs. , 1974, Research communications in chemical pathology and pharmacology.
[436] D Hoffmann,et al. The pH of tobacco smoke. , 1974, Food and cosmetics toxicology.
[437] Beckett Ah,et al. Proceedings: In vitro metabolic N-oxidation of the minor tobacco alkaloids, (-)methylanabasine and (-)anabasine to yield a hydroxylamine and a nitrone in lung and liver homogenates. , 1973 .
[438] P. Jenner,et al. Comparative in vitro hepatic metabolism of some tertiary N-methyl tobacco alkaloids in various species. , 1973, Research communications in chemical pathology and pharmacology.
[439] P. Jenner,et al. Species Variation in the Metabolism of R-(+)- and S-(-)-Nicotine by α-C- and N-Oxidation in vitro , 1973 .
[440] P. Murphy. Enzymatic oxidation of nicotine to nicotine 1'(5') iminium ion. A newly discovered intermediate in the metabolism of nicotine. , 1973, The Journal of biological chemistry.
[441] D. Hutson. Biological Oxidation of Nitrogen in Organic Molecules , 1973 .
[442] A. Beckett,et al. Proceedings: In vitro metabolic N-oxidation of the minor tobacco alkaloids, (-)methylanabasine and (-)anabasine to yield a hydroxylamine and a nitrone in lung and liver homogenates. , 1973, The Journal of pharmacy and pharmacology.
[443] P. Jenner,et al. Species variation in the metabolism of R-(+)- and S-(-)-nicotine by alpha-C- and N-oxidation in vitro. , 1973, Xenobiotica; the fate of foreign compounds in biological systems.
[444] P. Jenner,et al. A possible relation between pKa1 and lipid solubility and the amounts excreted in urine of some tobacco alkaloids given to man , 1972, The Journal of pharmacy and pharmacology.
[445] P. Jenner,et al. Absorption of (−)‐nicotine‐1′‐N‐oxide in man and its reduction in the gastrointestinal tract , 1970, The Journal of pharmacy and pharmacology.
[446] W. Hayes,et al. Essays in toxicology , 1969 .
[447] va Grusz-Harday. Tdliche Nicotinvergiftungen@@@Fatal nicotine poisoning , 1967 .
[448] E. Grusz-Harday. [Fatal nicotine poisoning]. , 1967, Archiv fur Toxikologie.
[449] S. Vanov,et al. Comparison of pharmacological activity of nicotine and related alkaloids occurring in cigarette smoke. , 1965, Archives internationales de pharmacodynamie et de therapie.
[450] S. Schwartz,et al. ALTERNATE ROUTES IN THE METABOLIC DEGRADATION OF THE PYRROLIDINE RING OF NICOTINE. , 1964, The Journal of biological chemistry.
[451] N. Papadopoulos. FORMATION OF NORNICOTINE AND OTHER METABOLITES FROM NICOTINE IN VITRO AND IN VIVO. , 1964, Canadian journal of biochemistry.
[452] R. Pinsent,et al. A DESIGN FOR GENERAL PRACTICE. I. REINFORCEMENT FOR THE FAMILY DOCTOR. , 1963, Lancet.
[453] L. Turnbull,et al. The Synthesis of Hydroxycotinine and Studies on Its Structure1 , 1963 .
[454] L. Turnbull,et al. N-Methylation of nicotine ad cotinine in vivo. , 1963, The Journal of biological chemistry.
[455] S. Schwartz,et al. The Corrected Structure of a Ketoamide Arising from the Metabolism of (-)-Nicotine , 1962 .
[456] E. Bowman,et al. Studies on the metabolism of (-)-cotinine in the human. , 1962, The Journal of pharmacology and experimental therapeutics.
[457] L. Turnbull,et al. Norcotinine (desmethylcotinine) as a urinary metabolite of nornicotine. , 1961, Journal of medicinal and pharmaceutical chemistry.
[458] L. Turnbull,et al. Metabolism of nicotine in the human and excretion of pyridine compounds by smokers. , 1959, The Journal of pharmacology and experimental therapeutics.